Premium
Von Willebrand's disease and angiodysplasia treated with thalidomide
Author(s) -
HIRRI H. M.,
GREEN P. J.,
LINDSAY J.
Publication year - 2006
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2006.01210.x
Subject(s) - angiodysplasia , medicine , thalidomide , von willebrand factor , octreotide , von willebrand disease , blood loss , surgery , gastroenterology , multiple myeloma , platelet , somatostatin
Summary. A 54‐year‐old man with type IIB VWD and severe angiodysplasia had such a large blood loss from the bowel that it was difficult to keep up with transfusion requirements. Treatment with factor eight concentrate barely slowed the loss. D.D.A.V.P., Octreotide, and recombinant activated Factor VII, tried separately, were ineffective. The use of Thalidomide at a dose of 150 mg daily has rendered him free from blood loss for the last six months and we suggest would be worth a trial in similar cases.